VISCHER advised Blue Owl (NYSE: OWL) on all Swiss legal aspects of the financing transaction, including an up to USD 500 million term loan facility for Madrigal Pharmaceuticals (NASDAQ: MDGL). Blue Owl is a leading asset manager redefining alternatives and Madrigal Pharmaceuticals is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis.

The VISCHER team was led by Dr. Adrian Dörig and included Christian Schneiter and Dr. Balthasar Müller (all Financing) as well as Christoph Niederer (Tax).

Author: Christian Schneiter